Vertex says Health Canada grants expanded use of Kalydeco

Vertex Pharmaceuticals announced that Health Canada has granted market authorization for the expanded use of Kalydeco for the treatment of cystic fibrosis in children ages two months and older weighing at least three kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D,G178R, G551S, S1251N, S1255P, S549N, S549R or R117H. “For the first time, children with specific mutations will be eligible at 2 months of age for a medicine that treats the underlying cause of their cystic fibrosis,” said Michael Siauw, General Manager at Vertex Pharmaceuticals.